PARP1 and neoplasm: Joydeep Mukherjee et al. demonstrated that PARP inhibitors such as olaparib involve the stimulation of c-NHEJ-dependent (classical non-homologous end joining) telomere fusion and selectively kill ALT+ tumor cells [95].